These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34179409)

  • 1. Interrupted Identities: Autologous Stem Cell Transplant in Patients With Multiple Myeloma.
    Halpin SN; Konomos M; Jowers I
    J Patient Exp; 2021; 8():2374373521998864. PubMed ID: 34179409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study.
    Camilleri M; Bekris G; Sidhu G; Buck C; Elsden E; McCourt O; Horder J; Newrick F; Lecat C; Sive J; Papanikolaou X; Popat R; Lee L; Xu K; Kyriakou C; Rabin N; Yong K; Fisher A
    Support Care Cancer; 2022 Sep; 30(9):7469-7479. PubMed ID: 35657402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Iterative Formative Evaluation of Medical Education for Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant.
    Halpin SN; Konomos M
    J Cancer Educ; 2022 Jun; 37(3):779-787. PubMed ID: 32978725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.
    Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M
    Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining the optimal time for bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplant in the treatment of multiple myeloma.
    Liu J; Li J; Huang B; Zheng D; Chen M; Zhou Z; Xu D; Zou W
    Chin J Cancer Res; 2013 Apr; 25(2):166-74. PubMed ID: 23592897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis.
    Yadav N; Mirgh SP; Aggarwal M; Agrawal N; Mehta P; Khushoo V; Kapoor J; Bhatia N; Agrawal P; Ahmed R; Bhurani D
    Indian J Cancer; 2023; 60(3):316-324. PubMed ID: 37787191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
    Hashmi H; Atrash S; Jain J; Khasawneh G; Mohan M; Mahmoudjafari Z; Cui W; McGuirk J; Shune L; Ahmed N; Abdallah AO
    Transplant Cell Ther; 2023 Apr; 29(4):262.e1-262.e6. PubMed ID: 36682468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of tandem stem cell transplantation for multiple myeloma patients.
    Martino M; Recchia AG; Fedele R; Neri S; Vincelli ID; Moscato T; Gentile M; Morabito F
    Expert Opin Biol Ther; 2016; 16(4):515-34. PubMed ID: 26698133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population.
    Cherniawsky HM; AlAhwal H; Mourad YA; Forrest D; Gerrie A; Kuchenbauer F; Nantel SH; Narayanan S; Nevill T; Power M; Sanford D; Toze C; White J; Escano L; Sutherland H; Song K
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):476-482. PubMed ID: 33814336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
    Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
    Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of post-transplant bone marrow plasma cell percent in multiple myeloma patients undergone autologous transplantation.
    Hwang IH; Chung JS; Shin HJ; Choi YJ; Song MK; Seol YM; Cho GJ; Choi BG; Choi MK; Choi BK; Ahn KH; Shin KH; Lee HS; Nam HS; Hwang JM
    Korean J Intern Med; 2011 Mar; 26(1):76-81. PubMed ID: 21437166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial.
    Striha A; Ashcroft AJ; Hockaday A; Cairns DA; Boardman K; Jacques G; Williams C; Snowden JA; Garg M; Cavenagh J; Yong K; Drayson MT; Owen R; Cook M; Cook G
    Trials; 2018 Mar; 19(1):169. PubMed ID: 29514706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Liang EC; Muffly LS; Shiraz P; Shizuru JA; Johnston L; Arai S; Frank MJ; Weng WK; Lowsky R; Rezvani A; Meyer EH; Negrin R; Miklos DB; Sidana S
    Transplant Cell Ther; 2021 May; 27(5):405.e1-405.e6. PubMed ID: 33775587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
    Marchesi F; Mengarelli A; Giannotti F; Tendas A; Anaclerico B; Porrini R; Picardi A; Cerchiara E; Dentamaro T; Chierichini A; Romeo A; Cudillo L; Montefusco E; Tirindelli MC; De Fabritiis P; Annino L; Petti MC; Monarca B; Arcese W; Avvisati G;
    Transpl Infect Dis; 2014 Feb; 16(1):158-64. PubMed ID: 24215479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience of Autologous Stem Cell Transplant in Multiple Myeloma: The Patient and Caregiver Perspective.
    Hansen DK; Bixby T; Fixler K; Shea L; Brittle C; Brunisholz K; Liu YH; Huo JS
    J Patient Exp; 2023; 10():23743735231202733. PubMed ID: 37766811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.
    Kansagra A; Gonsalves WI; Gertz MA; Buadi FK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Kapoor P; Muchtar E; Kourelis TV; Warsame R; Leung N; Zeldenrust SR; Lust JA; Rajkumar SV; Kyle RA; Hogan W; Kumar SK
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2127-2132. PubMed ID: 29656139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.